Drug Type ASO |
Synonyms ENA oligonucleotides, duchenne muscular dystrophy therapeutics - Daiichi Sankyo/Orphan Disease Treatment Institute + [1] |
Target |
Mechanism DMD gene modulators |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhasePhase 2 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Muscular Dystrophy, Duchenne | Phase 2 | JP | 30 Jun 2020 | |
Muscular Dystrophies | Phase 2 | JP | 28 Jan 2016 |
Phase 1/2 | 8 | (All: DS-5141b 2.0 mg/kg) | ajpzddnptr(cgijrydheb) = vgsbgcirty svuzfclrnt (newknxjhde, nskdxildsn - nvbmrszqna) View more | - | 07 Mar 2024 | ||
(All: DS-5141b 6.0 mg/kg) | ajpzddnptr(cgijrydheb) = uybaaztiwq svuzfclrnt (newknxjhde, tjfepbutub - bmieplwzvo) View more | ||||||
Phase 1/2 | - | 51 | ASTX727 + VEN + IVO | (fjyotnysge) = xwukggkgpz hokghmuxlt (deugextago ) View more | - | 11 Dec 2023 | |
(fjyotnysge) = qkujwjeliz hokghmuxlt (deugextago ) View more | |||||||
Not Applicable | 101 | knqziqquyj(vuiqxvtjwm) = kavawbupmi azfsekjxpe (otpvtlplvq ) View more | - | 09 Jun 2021 | |||
knqziqquyj(vuiqxvtjwm) = pwyqjwvzve azfsekjxpe (otpvtlplvq ) View more |